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The association between aspirin use and lung cancer risk in women was examined in a case–control study nested in the New
York University Women’s Health Study, a large cohort in New York. Case subjects were all the 81 incident lung cancer cases
who had provided information about aspirin use at enrollment and during the 1994–1996 follow up. Ten controls per case
were randomly selected from among study participants who matched a case by age, menopausal status, and dates of
enrollment and follow-up. Relative to no aspirin use, the odds ratio for lung cancer (all histological sub-types combined)
among subjects who reported aspirin use three or more times per week for at least 6 months was 0.66 (95% conﬁdence
interval 0.34–1.28), after adjustment for smoking and education. A stronger inverse association was observed in analyses
restricted to non-small cell lung cancer (adjusted odds ratio 0.39, 95% conﬁdence interval 0.16–0.96). These results suggest
that regular aspirin use might be inversely associated with risk of lung cancer in women, particularly the non-small cell sub-type.
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A role for nonsteroidal anti-inﬂammatory drugs (NSAIDs) in
preventing lung carcinogenesis is suggested by animal models, in
which aspirin and other NSAIDs inhibited the formation of chemi-
cally-induced lung tumours (Jalbert and Castonguay, 1992;
Castonguay et al, 1998; Rioux and Castonguay, 1998).
The relation between NSAIDs use and lung cancer has been exam-
ined in at least six epidemiological studies published to date. In a trial
of aspirin among British physicians, there were fewer lung cancer
deaths among aspirin users compared with nonusers (Peto et al,
1988). In two prospective studies, no overall association was observed
between aspirin use and lung cancer, although when stratiﬁed by
gender, regular aspirin use appeared to be inversely associated with
lung cancer incidence (Paganini-Hill et al, 1989) and mortality (Thun
et al, 1993) in women. In a prospective study based on the ﬁrst
National Health and Nutrition Examination Survey, self-reported
use of aspirin during the 30-day period preceding a subject’s recruit-
ment into the cohort was associated with a signiﬁcant reduction in
lung cancer incidence compared with nonuse (Schreinemachers
and Everson, 1994). Two case–control studies found no signiﬁcant
associations between aspirin use and risk of lung cancer (Rosenberg,
1995; Langman et al, 2000).
To assess further the potential effect of aspirin use on lung
cancer risk, we analysed the data in a case–control study of lung
cancer nested in the New York University (NYU) Women’s Health
Study cohort.
MATERIALS AND METHODS
Study population
The NYU Women’s Health Study is a long-term prospective cohort
study that has been described in detail elsewhere (Toniolo et al,
1991, 1995). Brieﬂy, between March 1985 and June 1991, 14275
mostly Caucasian women between ages of 31 and 70 years were
enrolled at a mammography screening clinic in New York City.
Women, who in the preceding 6 months had neither used hormo-
nal medications nor been pregnant, were eligible for enrollment. At
the time of their recruitment into the cohort, study subjects
answered a self-administered questionnaire focusing on demo-
graphic, anthropometric, reproductive and dietary data, medical
history and medication use. Approximately every 2 years, follow-
up questionnaires were mailed to all cohort members to update
the information on potential risk factors and to identify newly
diagnosed cases of cancer and other medical conditions. Written
informed consent was obtained from all subjects. The study was
reviewed and approved annually by the Institutional Board of
Research Associates of NYU School of Medicine.
Ascertainment of exposure
Information on individual use of aspirin and other NSAIDs was
obtained at baseline and in a more detailed format in the 1994–
1996 follow-up questionnaire. The baseline questionnaire (1985–
1991) included the following question: In the last 4 weeks, have you
taken pain killers such as Aspirin, Motrin, Naprosyn, etc.? For subjects
who responded positively, speciﬁc information, including the name
of the drug and when last taken, was collected. Subjects who reported
use of any drug recorded in the Physicians’ Desk Reference
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edition as containing acetylsalicylic acid, were classiﬁed as exposed
to aspirin at baseline. In the 1994–1996 follow-up questionnaire,
additional information on aspirin use was collected by means of
the following question: Have you taken Aspirin three or more times
per week for a period of 6 months or longer? For those who answered
positively, we queried the age when aspirin use started, the age when
it stopped and total duration of treatment.
Identiﬁcation of cases
Lung cancer cases were identiﬁed primarily through active follow-
up either during annual visits for mammographic screening (up to
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member approximately every 2 years. The active follow-up was
supplemented with regular record linkages with the statewide
Tumor Registries of New York, New Jersey, Connecticut and Flor-
ida, and with the US National Death Index. For each reported case
of lung cancer, we requested individuals, or their next of kin, for
permission to obtain a copy of the pertinent medical and pathol-
ogy reports.
Case–control study
As of 1 July, 2000, after a median follow-up of 12 years (137700
person-years), 144 women with incident lung cancer were identi-
ﬁed. Pathological conﬁrmation of these lung cancer cases was
achieved either through medical record review (96 cases) or
through linkages with Tumor Registries (42 cases). For six reported
cases of lung cancer the pathology reports were not available at the
time of the study. Because of the high concordance between
reported and independently conﬁrmed lung cancer in our study,
these cases were retained in the ﬁnal analyses.
Ten controls per case were selected at random among cohort
members who were alive and free of cancer at the time of the diag-
nosis of a given case and who matched the case on age at
enrollment (+6 months), menopausal status at enrollment, date
of enrollment (+6 months) and date of response to the 1994–
1996 follow-up questionnaire (+6 months). As a result, 1584
women were eligible for the case–control study, including 144
cases of lung cancer and 1440 individually matched controls.
Of the 1584 eligible subjects, 1507 (81 lung cancer cases, 1426
controls) had replied to questions on aspirin use in the 1994–
1996 follow-up questionnaire. Among the latter, 618 were
controls from matched sets containing non-respondent cases
and were dropped. As a result, 81 lung cancer cases and 808
individually-matched control subjects were considered for study.
Of the 81 lung cancer cases, 51 had answered the questions
about long-term aspirin use prior to their diagnosis and 30 cases
after diagnosis.
Data analysis
Information on potential confounders, such as age, menopausal
status, and body mass index (BMI; weight in kilograms divided
by height in meters squared), was obtained from the baseline ques-
tionnaire. Detailed information on race/ethnicity, educational
status and smoking history was collected using subsequent
follow-up questionnaires. Information on aspirin use was obtained
from the baseline and the 1994–1996 follow-up questionnaires, as
described above.
Within each matched set, aspirin exposure was discounted for
both cases and corresponding controls if it occurred after the date
of diagnosis of the case. In addition, we also discounted aspirin
exposures within 1 year of the date of diagnosis by censoring aspir-
in exposures occurring after the index date (date of diagnosis – 1
year) for both cases and their matched controls. A lag period of 1
year was chosen to prevent the possibility of protopathic bias, i.e.,
aspirin use by case subjects might have been the result of early
symptoms of an undiagnosed disease and therefore be a conse-
quence of, rather than a risk factor for, disease.
Conditional logistic regression analysis appropriate for matched
case–control data was used to assess the association between
aspirin use and lung cancer. Potential confounders were selected
with a backward elimination strategy, decided upon a priori to
avoid overadjustment (Day et al, 1980). This approach resulted
in two statistically signiﬁcant determinants of lung cancer risk:
smoking history and educational status (P50.001 and 0.03,
respectively). Adjustment for potential confounders for lung
cancer was performed by means of inclusion of variables for
smoking (never, past, current) and education (no college,
attended college, attended graduate school) in the multivariate
model. Results are expressed as odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs). Tests for trend were conducted by using
likelihood ratio statistics in the conditional logistic regression
models.
RESULTS
The majority of women in the case–control study were Caucasian
(82%), 11% were African American and 7% reported other ethni-
cities. This ethnic composition reﬂects the characteristics of the
patient population in the screening clinic at the time of recruit-
ment. Because of matching, the cases and controls had similar
proportions of premenopausal and postmenopausal women (25
and 75%, respectively) at baseline and identical age at enrollment
(mean 56 years, range 35–69 years). Common histopathological
types of lung cancer were observed: 62 non-small cell types (37
adenocarcinomas, 16 bronchoalveolar adenocarcinomas, 4 squa-
mous cell carcinomas, 3 large cell carcinomas, 2 adenosquamous
carcinomas), 8 small cell carcinomas, 4 malignant carcinoid
tumours, 1 sarcoma, and 6 tumours of unknown histology. Among
the cases, the mean age at diagnosis was 64 years (range 39–78
years) and the mean period between date of enrollment and date
of diagnosis was 8 years (range 0.2–14 years).
Selected characteristics of the cases and the controls are
presented in Table 1. Compared to never smokers, women who
reported past smoking had a signiﬁcantly higher risk of lung
cancer (OR 3.97, 95% CI 2.04–7.71). The association was stron-
ger among women who reported recent smoking during the
follow-up period (OR 8.03, 95% CI 3.68–17.54). A signiﬁcant
positive trend was observed between the pack-years of cigarette
smoking and risk of lung cancer (P for trend 50.001). In univari-
ate analyses, body mass index and educational status were
inversely associated with the risk of lung cancer (Table 1).
However, after adjustment for smoking history the inverse asso-
ciation remained signiﬁcant only for educational status (P for
trend 50.05).
Exposure to aspirin in the 4 weeks preceding the enrollment did
not appear to inﬂuence lung cancer risk (unadjusted OR 1.02, 95%
CI 0.69–1.50). Adjustments for smoking and educational status
did not change the risk estimate substantially (adjusted OR 0.93,
95% CI 0.56–1.53). Compared with nonusers, the odds ratio for
lung cancer (all types) among women who reported aspirin use
three or more times per week for a period of at least 6 months
was 0.66 (95% CI 0.34–1.28) after adjustment for smoking and
educational status (Table 2).
Because previous studies have shown that increased cyclo-oxyge-
nase-2 (COX-2) expression occurs preferentially in non-small cell
lung cancers, and particularly, in adenocarcinomas and squamous
cell carcinomas (Hida et al, 1998; Wolff et al, 1998; Ochiai et al,
1999), we analysed the association between aspirin use and lung
cancer risk in a subset of 62 non-small cell lung cancer cases
and 618 matching controls. Short-term aspirin use during the 4-
week period prior to the enrollment was not associated with risk
of non-small cell lung cancer (adjusted OR 0.96, 95% CI 0.56–
1.63). Regular aspirin use for at least 6 months was inversely asso-
ciated with risk of non-small cell lung cancer after controlling for
smoking and educational status (adjusted OR 0.39, 95% CI 0.16–
0.96). A signiﬁcant inverse trend was observed between duration of
aspirin use and risk of non-small lung cancer (P for trend=0.02)
(Table 2).
Because 30 of the 81 cases reported on their long-term aspirin
use after having been diagnosed with lung cancer, the above
analyses were repeated after the exclusion of these cases and their
matched controls. In these analyses (51 cases, 510 controls), regular
aspirin use resulted in adjusted odds ratios of 0.54 (95% CI 0.23–
1.24) for all types of lung cancer and 0.23 (95% CI 0.07–0.81) for
non-small cell lung cancer, as compared with non-use.
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In a study of mostly Caucasian women in New York City, long-
term aspirin use (for a period of at least 6 months) was inversely
associated with the risk of lung cancer. The inverse association was
particularly evident in relation to non-small cell lung cancer. After
adjustment for smoking and educational status, the inverse associa-
tion between long-term aspirin use and non-small cell lung cancer
appeared to be stronger among women who reported aspirin use
for a longer period of time (at least 5 years). Short-term aspirin
use (during the 4-week period prior to enrollment) was not asso-
ciated with risk of lung cancer (both all-types and non-small cell
types).
Several methodological issues should be considered in the inter-
pretation of the study results. The study limitations included the
relatively small number of lung cancer cases, the dependence on
a self-administered questionnaire for exposure assessment and lack
of information on the indication, the dose and the precise duration
of aspirin use. An additional concern was that information about
long-term aspirin exposure was collected after the enrollment of
study subjects in the cohort and, for a substantial proportion of
the cases, after the occurrence of lung cancer, which raises the
possibility of recall and survival biases. The recall bias may have
been less likely because the exclusion of 30 cases who reported
long-term aspirin use after the diagnosis did not affect the results
signiﬁcantly. Indeed, we would have expected recall bias to operate
in the opposite direction to that observed, i.e., a tendency for cases
to better recall an exposure would result in odds ratios greater than
one rather than the inverse association observed here.
Survival bias is of concern for diseases characterised by poor
prognosis, including lung cancer. Indeed, 63 cases (44%) had died
before the mailing of the questionnaire eliciting information on
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Table 1 Characteristics of the study population and odds ratios for lung cancer, NYU Women’s Health Study, 1985–
2000
Characteristic
Cases
No.
Controls
No.
OR
Unadjusted
a 95% CI
OR
Adjusted
b 95% CI
Body mass index, (kg m
72) quartiles
c,d
1 (16.4–22.1) 25 194 1.00 Reference 1.00 Reference
2 (22.2–24.2) 21 212 0.76 0.41–1.41 0.71 0.36–1.38
3 (24.3–27.4) 19 189 0.79 0.42–1.48 0.77 0.38–1.55
4 (27.5–51.4) 15 209 0.55 0.28–1.10 0.64 0.31–1.32
Race/Ethnicity
e
Caucasian 61 665 1.00 Reference 1.00 Reference
African American 8 87 1.02 0.47–2.22 1.09 0.48–2.46
Other 12 56 2.30 1.17–4.50 1.26 0.47–3.35
Education
e,f
No College 36 297 1.00 Reference 1.00 Reference
Attended College 23 299 0.62 0.50–1.29 0.62 0.35–1.08
Attended Graduate School 12 209 0.46 0.27–0.95 0.51 0.25–1.03
Smoking history
e,g
Never 12 393 1.00 Reference
Past 41 332 3.97 2.04–7.71
Current 20 83 8.03 3.68–17.5
Cigarette smoking, pack–years
g
0 12 337 1.00 Reference
1–9 3 105 0.81 0.22–2.96
10–25 12 98 3.28 1.41–7.62
26–45 20 100 5.56 2.60–11.9
445 24 66 9.73 4.64–20.4
aAnalysis matched on age, menopausal status, dates of enrollment and follow-up.
bAdjusted for smoking history (never, past, current).
cData from the baseline questionnaire. Data were msising for body mass index (1 case, 4 controls).
dP for trend=0.11.
eData from the
follow-up questionnaires. Data were missing for education (10 cases, 3 controls) and smoking history (8 cases).
fP for trend50.05.
gP for
trend50.001.
Table 2 Aspirin use and odds ratios for lung cancer, NYU Women’s Health Study, 1985–2000
Lung Cancer
All types Non-small cell
Aspirin use Cases Controls OR
a OR
b 95% CI Cases Controls OR
a OR
b 95% CI
Ever use aspirin use three or more times
per week for at least 6 months
No 66 656 1.00 1.00 Reference 53 506 1.00 1.00 Reference
Yes 15 152 0.98 0.66 0.34–1.28 9 112 0.76 0.39 0.16–0.96
Duration of use, years
55 6 61 0.98 0.60 0.21–1.76 5 45 1.05 0.48 0.14–1.66
55 9 91 0.99 0.68 0.31–1.51 4 67 0.57 0.33 0.10–1.11
P for trend 0.25 0.02
aAnalysis matched on age, menopausal status, dates of enrollment and follow-up.
bAdjusted for smoking (never, past, current) and educational status (no college, attended
college, attended graduate school).
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analyses of follow-up data. If aspirin use were associated with
reduced survival following diagnosis, the proportion of aspirin
users among case survivors would be lower than among controls,
leading to an apparent inverse association between aspirin use
and risk of lung cancer that would be spurious. The evidence on
the effect of aspirin on survival of lung cancer patients is limited.
However, several studies have shown that overexpression of COX-
2, which is inhibited by aspirin, is associated with poor prognosis
in lung cancer (Achiwa et al, 1999; Khuri et al, 2001), suggesting
that if aspirin has an effect on survival in lung cancer, it is more
likely to be beneﬁcial than detrimental. In this case, the effect of
survival bias would attenuate a real inverse association between
aspirin use and lung cancer, suggesting that the protective effect
of aspirin could in fact be larger than we observed.
To ensure that only relevant aspirin exposures were considered,
we discounted exposures occurring after the diagnosis and within 1
year before diagnosis for each case and corresponding controls. An
additional concern was the possibility of confounding by indica-
tion. Due to the lack of data on the reasons for aspirin use in
our study, we were unable to separate the effects of aspirin from
the indications for aspirin use. We also considered a possibility
of exposure misclassiﬁcation resulting from the inability to verify
the use of cold remedies and other combined preparations contain-
ing acetylsalicylic acid, which may inﬂuence the observed
association. However, one would expect such misclassiﬁcation to
be non-differential, with a tendency to obscure rather than estab-
lish associations.
The observed inverse association between long-term aspirin use
and risk of lung cancer is in agreement with previous epidemiolo-
gical studies suggesting that aspirin use could be associated with at
least a moderately reduced risk of lung cancer (Peto et al, 1988;
Schreinemachers and Everson, 1994). The observed association is
also consistent with experimental evidence indicating that chemo-
preventive effects of aspirin and other NSAIDs could be
mediated through the inhibition of COX-2 enzyme, which appears
to be overexpressed in human lung carcinoma, particularly in non-
small cell lung cancer (Hida et al, 1998; Wolff et al, 1998; Ochiai et
al, 1999). In the lung, the interaction of inhaled particles with
alveolar macrophages and structural epithelial cells leads to the
inﬂammatory response characterised by activation of COX-2
enzyme, release of prostaglandins, leukotrienes, cytokines, reactive
oxygen species, and growth factors that are involved in local tissue
damage and remodelling (Janssen et al, 1993). The inﬂammatory
response is crucial in the activation of proto-oncogenes by carcino-
genic ﬁbres (Janssen et al, 1994), mutations in the alveolar
epithelial cells and subsequent development of lung neoplasia in
animal models (Dungworth et al, 1994; Borm and Driscoll, 1996).
Growing epidemiological evidence indicates that inﬂammation
may play an important role in lung cancer. Several studies have
found that inﬂammatory lung diseases, including asthma and
chronic bronchitis are associated with increased incidence of lung
cancer (Alavanja et al, 1992; Kallen et al, 1993; Vesterinen et al,
1993; Wu et al, 1995; Huovinen et al, 1997; Mayne et al, 1999;
Brownson and Alavanja, 2000; Brenner et al, 2001).
Aspirin and other NSAIDs share an ability to reduce inﬂamma-
tory responses by inhibiting the synthesis of prostaglandins from
arachidonic acid. Prostaglandins are important regulatory factors
of epithelial cell function and, under certain circumstances, prosta-
glandins can stimulate cell proliferation and suppress immune
response to neoplastic cells (Plescia et al, 1975). In addition, several
groups have shown that high concentrations of free arachidonic
acid can promote apoptosis, independently of prostaglandin forma-
tion (Surette et al, 1996; Chan et al, 1998; Longo et al, 1999). It has
been proposed that the increased expression of COX-2 may lower
the intracellular level of free arachidonic acid and thereby reduce
apoptosis (Prescott and Fitzpatrick, 2000). Consequently, the
chemopreventive effects of aspirin and other NSAIDs could result
from inhibition of COX-2, reduction of prostaglandin synthesis,
increased intracellular levels of free arachidonic acid, and induction
of apoptosis.
In conclusion, the results of the study suggest that regular aspir-
in use may be inversely associated with lung cancer in women,
indicating that aspirin may have broader chemopreventive proper-
ties than previously thought. Because regular aspirin use may
occasionally result in serious side effects, such as gastrointestinal
bleeding, hemorrhagic stroke, and aspirin-sensitive asthma, speciﬁc
recommendations regarding use of aspirin for prevention of lung
cancer should be deferred until conﬁrmation of the effect by larger
studies and determination of the effective dose and duration of use.
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